AnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference
February 25 2020 - 4:00PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation, today
announced that Hamza Suria, chief executive officer
of AnaptysBio, will present at the Cowen and Company 40th
Annual Health Care Conference on Tuesday, March 3,
2020 at 11:20 a.m. ET at the Boston Marriott
Copley Place.
A webcast of the presentation will be available through
the investor section of the AnaptysBio website. A replay
of the webcast will be available for 90 days following the
event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing
first-in-class antibody product candidates focused on unmet medical
needs in inflammation. The Company’s proprietary anti-inflammatory
pipeline includes its anti-IL-33 antibody etokimab, previously
referred to as ANB020, for the treatment of chronic rhinosinusitis
with nasal polyps, or CRSwNP, and eosinophilic asthma; its
anti-IL-36R antibody ANB019 for the treatment of rare inflammatory
diseases, including generalized pustular psoriasis, or GPP, and
palmoplantar pustulosis, or PPP; its anti-PD-1 agonist program,
ANB030, for treatment of certain autoimmune diseases where immune
checkpoint receptors are insufficiently activated, and its BTLA
modulator program, ANB032, which is broadly applicable to human
inflammatory diseases associated with lymphoid and myeloid immune
cell dysregulation. AnaptysBio’s antibody pipeline has been
developed using its proprietary somatic hypermutation, or SHM
platform, which uses in vitro SHM for antibody discovery and is
designed to replicate key features of the human immune system to
overcome the limitations of competing antibody discovery
technologies. AnaptysBio has also developed multiple therapeutic
antibodies in an immuno-oncology partnership with TESARO, a GSK
company, including an anti-PD-1 antagonist antibody (dostarlimab
(TSR-042)), an anti-TIM-3 antagonist antibody (TSR-022) and an
anti-LAG-3 antagonist antibody (TSR-033), and an inflammation
partnership with Celgene, including an anti-PD-1 checkpoint agonist
antibody (CC-90006) currently in clinical development.
Contact:Eric Loumeau AnapytsBio,
Inc.858.362.6348eloumeau@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024